Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

A Closer Look at the BZKF BORN-Project: Interview with Dr. Maurice Heimer from the Clinic and Polyclinic for Radiology at the LMU Klinikum

The Bavaria-wide Oncological Radiology Network (BORN) is now in its second funding phase and is making rapid progress. The project was initiated in…

Medical personnel looking at a technical device to discuss diagnostic guidelines

2,237 Patients, 11 Hospitals, four HCC Criteria: A Comparison Study

A recent study, conducted across 11 South Korean hospitals, compared the diagnostic performance of four hepatocellular carcinoma (HCC) diagnostic…

mint Lesion screenshot with HCC diagnosis according to APASL, AASLD, LI-RADS, KLCA-NCC, and EASL guidelines

Multicentric Study: Comparison of Diagnostic Guidelines for Hepatocellular Carcinoma

Recent advancements in MRI techniques and tumor biology have led to updated hepatocellular carcinoma (HCC) diagnostic guidelines from various liver…